Biophytis is developing Sarconeos (BIO101), a compound that activates the MAS receptor in order to target three critical downstream metabolic pathways: mTOR, AMPK, and MAPK. This compound recently completed a Phase 2b clinical trial as a therapy for sarcopenia, the age-related loss of muscle mass that leads to frailty and weakness, and it is using functional abilities, such as walking speed, as its endpoints. In August 2021, top-line results were released via a press release, which showed that the highest dose had a clinically meaningful improvement in gate speed as measured in the 400-meter walk test along with a good safety profile. A Phase 3 trial is now being planned.
A Phase 1/2 trial of Sarconeos for Duchenne muscular dystrophy is due to start in 2021, and a Phase 2/3 trial for COVID is currently underway.
Biophytis also has a second drug candidate, Macuneos (BIO201), in preclinical testing for dry age-related macular degeneration.
While this is a French company, it maintains a website in English.